Key facts
- PlusVitech’s last known valuation is $5.3M (Aug 2021).
- It has raised $4.5M; the latest was Later Stage VC ($3.5M) in Dec 2025.
- Notable investors include MassChallenge, INNVIERTE SICC, 3Fs (Spain), Capital Global Partners, Francisco Leon — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for PlusVitech
- ·The full record, as it builds
Funding rounds
No funding rounds for PlusVitech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PlusVitech
Developer of pharmaceutical treatments designed for non-invasive genetic cancer detection. The company's therapies focus on small-molecule, monoclonal antibodies instead of painful and time-consuming tissue biopsies, enabling doctors to detect and treat cancers early.
- Sector
- Healthcare
- HQ
- Sevilla, Spain
- Founded
- 2013
- Employees
- 2
- Website
- plusvitech.com/
- Ownership
- Privately Held (backing)
PlusVitech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PlusVitech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PlusVitech in its N-PORT filings yet. We sweep new filings monthly.